Compare UMBF & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UMBF | ICLR |
|---|---|---|
| Founded | 1913 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.3B |
| IPO Year | 2006 | 2001 |
| Metric | UMBF | ICLR |
|---|---|---|
| Price | $129.58 | $136.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | $138.90 | ★ $178.62 |
| AVG Volume (30 Days) | 543.2K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ 3.34 | N/A |
| EPS | ★ 3.35 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.07 | N/A |
| Revenue Next Year | $6.85 | N/A |
| P/E Ratio | $38.25 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $98.22 | $66.57 |
| 52 Week High | $136.11 | $211.00 |
| Indicator | UMBF | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 68.04 |
| Support Level | $122.02 | $99.11 |
| Resistance Level | $135.39 | $193.87 |
| Average True Range (ATR) | 2.89 | 6.97 |
| MACD | -0.41 | 2.16 |
| Stochastic Oscillator | 48.39 | 79.85 |
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.